Alpha-Synuclein Overexpressing Neurons

📖 Wiki Page

cell848 wordssynced 2026-04-02

Alpha-Synuclein Overexpressing Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein Overexpressing Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease Model Neurons</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Substantia nigra, cortex, other brain regions (model)</td>
</tr>
<tr>
<td class="label">Cell Types</td>
<td>AAV-Syn overexpression, iPSC-derived SNCA triplication neurons</td>
</tr>
<tr>
<td class="label">Primary Neurotransmitter</td>
<td>Dopamine (nigral), Glutamate (cortical)</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>Alpha-synuclein, Phospho-Ser129, TH, NeuN</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0004117](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0004117)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0004117](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0004117)</td>
</tr>
</table>

Introduction

...

Alpha-Synuclein Overexpressing Neurons

Introduction

Alpha-synuclein overexpressing neurons are disease model neurons that overexpress the SNCA gene encoding the alpha-synuclein protein. These models replicate the proteinaceous inclusions known as Lewy bodies and Lewy neurites, which are pathological hallmarks of Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These neurons are typically generated through viral vector-mediated gene delivery or derived from iPSCs carrying SNCA duplication/triplication mutations. [@spillantini1997]

Overview

Mermaid diagram (expand to render)

Multi-Taxonomy Classification

Taxonomy Database Cross-References

PanglaoDB Marker Cross-References

Unknown (PanglaoDB):

External Database Links

[Cell Ontology (CL:0004117)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0004117)
[OBO Foundry (CL:0004117)](http://purl.obolibrary.org/obo/CL_0004117)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[Human Cell Atlas](https://www.humancellatlas.org/)
[PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

PanglaoDB Marker Cross-References

Unknown (PanglaoDB):

External Database Links

[Cell Ontology (CL:0004117)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0004117)
[OBO Foundry (CL:0004117)](http://purl.obolibrary.org/obo/CL_0004117)
[Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
[CellxGene Census](https://cellxgene.cziscience.com/)
[PanglaoDB](https://panglaodb.se/)

Alpha-Synuclein Biology

Normal Protein Function

Alpha-synuclein is a 140-amino acid protein predominantly expressed in presynaptic terminals. Its normal functions include:

Synaptic vesicle regulation: Modulates synaptic vesicle pools and release
Dopamine synthesis: Influences tyrosine hydroxylase activity
Chaperone activity: Involved in protein folding homeostasis
Membrane binding: Associates with synaptic vesicles

Pathological Aggregation

In disease states, alpha-synuclein undergoes:

Misfolding: Conformational change from alpha-helix to beta-sheet

Oligomerization: Formation of toxic soluble oligomers

Fibrillization: Aggregation into insoluble fibrils

Inclusion formation: Lewy body and Lewy neurite development

SNCA Mutations and Copy Number Variants

A53T (SNCA^A53T): Early-onset familial PD
A30P (SNCA^A30P): Reduced membrane binding
E46K (SNCA^E46K): Increased aggregation
SNCA duplication: Sporadic PD risk factor
SNCA triplication: Parkinsoid syndrome (Dementia-Parkinsonism)

Cellular Phenotypes

Protein Aggregation

Lewy body-like inclusions: Cytoplasmic aggregates
Lewy neurites: Axonal and dendritic inclusions
Phospho-Ser129 alpha-synuclein: Pathological phosphorylation
Ubiquitin-positive aggregates: Proteostasis impairment

Synaptic Dysfunction

Reduced synaptic vesicle number: Depleted vesicle pools
Impaired dopamine release: Synaptic transmission deficits
Synaptic protein loss: Synaptophysin reduction
Neuronal connectivity deficits: Reduced dendritic branching

Mitochondrial Dysfunction

Complex I impairment: Electron transport chain defects
Mitochondrial fragmentation: Altered dynamics
Reduced ATP production: Bioenergetic failure
Increased mitochondrial ROS: Oxidative stress

Proteostasis Impairment

Lysosomal dysfunction: Reduced autophagic clearance
ER stress: Unfolded protein response activation
Proteasomal inhibition: Impaired protein degradation
Aggregate seeding: Spreading pathology

Mechanisms of Neurodegeneration

Toxic Oligomer Hypothesis

Soluble oligomeric forms of alpha-synuclein are considered the most toxic species:

Membrane pore formation: Causing ion dysregulation
Mitochondrial damage: Direct interaction with mitochondria
Synaptic dysfunction: Presynaptic terminal impairment
Spread prion-like behavior: Intercellular propagation

Prion-Like Propagation

Alpha-synuclein pathology can spread via:

Release: Secretion from affected neurons

Uptake: Internalization by neighboring cells

Template-directed misfolding: Inducing endogenous protein aggregation

Network spread: Connectome-dependent propagation

Inflammation

Microglial activation: Enhanced by extracellular alpha-synuclein
Cytokine release: IL-1β, TNF-α, IL-6 elevation
Oxidative stress: NADPH oxidase activation
Neuronal damage amplification: Inflammatory cascade

Function

Protein aggregation modeling: Lewy body formation
Synaptic dysfunction studies: Dopamine release impairment
Prion-like spreading: Pathology propagation mechanisms
Therapeutic target validation: Oligomer and aggregation inhibitors

Clinical Relevance

Disease Modeling

Alpha-synuclein overexpressing neurons enable study of:

Sporadic and familial PD mechanisms
Lewy body dementia pathology
Multiple system atrophy progression
Therapeutic intervention effects

Therapeutic Strategies

Aggregation Inhibitors

Small molecule inhibitors: E.g., Anle138b, CLR01
Antibody therapies: Anti-alpha-synuclein antibodies
Molecular tweezers: CLR01 (molecular disruptor)

Clearance Enhancement

Autophagy enhancers: Rapamycin, Trehalose
Lysosomal activators: GBA gene therapy
Immunotherapies: Active and passive vaccination

Neuroprotective Approaches

Antioxidants: MitoQ, N-acetylcysteine
Glutamate antagonists: NMDA receptor modulators
Growth factors: GDNF, BDNF

Research Applications

Drug Discovery Platforms

These models enable:

High-throughput screening for aggregation inhibitors
Target engagement studies
Mechanism of action determination
Biomarker development

Biomarkers

Phospho-Ser129: Pathological alpha-synuclein marker
Total alpha-synuclein: CSF and blood biomarker
Oligomeric alpha-synuclein: Toxic species detection
Neurofilament light chain: Neurodegeneration marker
[Alpha-Synuclein](/proteins/alpha-synuclein) SNCA Gene
[Parkinson's Disease](/diseases/parkinsons-disease)
[Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
Dopamine Neurons
Lewy Bodies

Background

The study of Alpha Synuclein Overexpressing Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org/)
[Lewy Body Dementia Association](https://www.lbda.org/)
[Parkinson's Foundation - Alpha-Synuclein](https://www.parkinson.org/)
[NCBI Gene - SNCA](https://www.ncbi.nlm.nih.gov/gene/6622)

📖 View canonical wiki page →